Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and oxidative stress in male patients with type 2 diabetes
2016-000370-38Phase 2Terminated
- Sponsor
- Rigshospitalet
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin arm with Placebo arm (2 arms). Primary endpoints: Urinary 8-oxo-guanosine excretion and Urinary 8-oxo-deoxyguanosine excretion. Started Feb 2016; status: terminated.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-000370-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000370-38.